Table 1.
Standard dose and renal dose at different kidney disease stage
| Dosage of drugs in adult patients with renal impairment (SARS-COV-2 disease) | |||||||
|---|---|---|---|---|---|---|---|
| Drug | Dose (normal renal function) | CrCl > 50–90 | CrCl 10–50 | CrCL < 10 | Hemodialysis | CAPD | CRRT |
| Antimalarials | |||||||
| Cloroquine phosphate | 500 mg po q12h | 500 mg q12h | 500 mg q12h | Reducing dose 50% | Reducing dose 50% | Reducing dose 50% | No adjustment required |
| Hydroxychloroquine sulfate | 200 mg po q8h or q12h | 200 mg q8 h or q12h | CrCl 15–30: 200 mg q24h | CrCl < 15: 200 mg alterative days | 200 mg alterative days | No data available | No data available |
| Antibiotics | |||||||
| Azithromycin | 250–500 mg IV/po q24h | 250–500 mg q24h | 250–500 mg q24h | 250–500 mg q24h | 250–500 mg q24h | 250–500 mg q24h | 250–500 mg q24h |
| Antivirals | |||||||
| Lopinavir/ritonavir | 400/100 mg po q12h | 400/100 mg q12h | 400/100 mg q12h | 400/100 mg q12h | 400/100 mg q12h | 400/100 mg q12h | No adjustment required |
| Darunavir/cobicistat | 1 tab (800/150 mg) po q24h | 1 tab (800/150 mg) q24h | 1 tab (800/150 mg) q24h | 1 tab (800/150 mg) q24h | 1 tab (800/150 mg) q24h | 1 tab (800/150 mg) q24h | No adjustment required |
| Favipavir | 1600 mg po q12h on Day 1 followed by 600 mg q12h | No data available | No data available | No data available | No data available | No data available | No data available |
| Remdesivir | 200 mg po q24h on Day 1 followed by 100 mg q24h | 200 mg poq24h on day 1 followed by 100 mg q24h | CrCl 50–30: 200 mg po q24h on Day 1 followed by 100 mg q24h | CrCl < 30: Avoid use | Avoid use | Avoid use | Avoid use |
| Monoclonal antibody | |||||||
| Tocilizumab | 8 mg/Kg q12 h | No adjustment required | No adjustment required | No adjustment required | No data available | No data available | No data available |
| Eculizumab | 900 mg IV every 7 days | No adjustment required | No adjustment required | No adjustment required | No data available | No data available | No data available |
| Sarilumab | No data available | No adjustment required | No adjustment required | No adjustment required | No adjustment required | No adjustment required | No adjustment required |
| Anakinra | 100 mg by IV infusion every 6 h (total of 400 mg daily) for 15 days | No adjustment required | No adjustment required | No adjustment required | No adjustment required | No adjustment required | No adjustment required |
| Corticosteroids | |||||||
| Desametasone | 1–2 mg/Kg IV/po q24h | 1–2 mg/Kg q24h | 1–2 mg/Kg q24h | 1–2 mg/Kg q24h | 20 mg q24h for 5 days followed by 10 mg q24h for 5 days | No data available | No data available |
| Methylprednisolone | 40–80 mg IV q24h | 40–80 mg IV q24h | 40–80 mg IV q24h | 40–80 mg IV q24h | No data available | No data available | No data available |
CrCl creatinine clearance, CAPD continuous ambulatory peritoneal dialysis, CRRT continuous renal replacement therapy, IV intravenous, Po oral dosage